Trial of D-Cycloserine in Schizophrenia
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00000371 |
Recruitment Status :
Completed
First Posted : November 3, 1999
Results First Posted : September 10, 2014
Last Update Posted : September 10, 2014
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
To characterize further the effects of D-cycloserine augmentation of antipsychotic treatment on negative symptoms, performance on neurocognitive tasks, and on markers for glutamatergic, dopaminergic and serotonergic function in serum and cerebrospinal fluid. To determine if negative symptoms and cognitive function improve over time, if these improvements meaningfully impact quality of life factors, if they correlate with markers of neuronal function, and if subpopulations can be identified according to response.
Dysfunction of glutamatergic neuronal systems has recently been implicated in the pathophysiology of schizophrenia based on the finding that non-competitive inhibitors of the NMDA receptor can reproduce in normals the positive symptoms, negative symptoms, and cognitive deficits of schizophrenia. Furthermore, glutamatergic dysfunction may alter forebrain dopaminergic neuronal activity, a system central to the antipsychotic action of typical neuroleptics. It is believed that enhancing NMDA receptor function by systemic treatment with D-cycloserine, a partial agonist at the glycine modulatory site of the NMDA receptor, will reduce symptoms in schizophrenia.
Sixty schizophrenic outpatients with prominent, primary negative symptoms are treated with antipsychotic medication and are randomly assigned to D-cycloserine or placebo for a 6-month, fixed-dose trial. The primary outcome measure is the total score on the Scale for Assessment of Negative Symptoms (SANS). A neuropsychological battery, which emphasizes tests sensitive to prefrontal cortical function, is administered. Blood is obtained at several time points and CSF is obtained at Week 8 for assay of concentrations of D-cycloserine, glutamate, HVA, and 5HIAA.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Schizophrenia | Drug: D-cycloserine Drug: Placebo | Phase 3 |
To characterize further the effects of D-cycloserine augmentation of antipsychotic treatment on negative symptoms, performance on neurocognitive tasks, and on markers for glutamatergic, dopaminergic, and serotonergic function in serum and cerebrospinal fluid. To determine if negative symptoms and cognitive function improve over time, if these improvements meaningfully impact quality of life factors, if they correlate with markers of neuronal function, and if subpopulations can be identified according to response.
Dysfunction of glutamatergic neuronal systems has recently been implicated in the pathophysiology of schizophrenia based on the finding that non-competitive inhibitors of the NMDA receptor can reproduce in normals the positive symptoms, negative symptoms and cognitive deficits of schizophrenia. Furthermore, glutamatergic dysfunction may alter forebrain dopaminergic neuronal activity, a system central to the antipsychotic action of typical neuroleptics. It is believed that enhancing NMDA receptor function by systemic treatment with D-cycloserine, a partial agonist at the glycine modulatory site of the NMDA receptor, will reduce symptoms in schizophrenia.
Sixty schizophrenic outpatients with prominent, primary negative symptoms are treated with antipsychotic medication and are randomly assigned to D-cycloserine or placebo for a 6-month, fixed-dose trial. The primary outcome measure is the total score on the Scale for Assessment of Negative Symptoms (SANS). A neuropsychological battery, which emphasizes tests sensitive to prefrontal cortical function, is administered. Blood is obtained at several time points and CSF is obtained at Week 8 for assay of concentrations of D-cycloserine, glutamate, HVA, and 5HIAA.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 60 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Six Month, Placebo-Controlled Trial of D-Cycloserine Co-Administered With Conventional Antipsychotics in Schizophrenia Patients |
Study Start Date : | August 1996 |
Actual Primary Completion Date : | April 2002 |
Actual Study Completion Date : | April 2002 |

Arm | Intervention/treatment |
---|---|
Experimental: D-Cycloserine
Subjects were given 50 mg/day of D-Cycloserine for 24 weeks
|
Drug: D-cycloserine
50 mg/daily by mouth
Other Name: Cycloserine |
Placebo Comparator: Placebo
Participants were given 50 mg/day of Placebo for 24 weeks.
|
Drug: Placebo
50 mg/day of placebo by mouth |
- Scale for the Assessment of Negative Symptoms (SANS) [ Time Frame: Baseline, Week 4, Week 8 ]The slope of SANS total score from baseline to week 8 in the treatment and placebo groups on the scale for the assessment of negative symptoms (SANS) total score. Total SANS scores range from 0-100. The SANS is comprised of 5 subscores: Affective Flattening or Blunting (score range 0-35), Alogia (score range 0-20), Avolition-Apathy (score range 0-15), Anhedonia-Asociality (score range 0-20), and Attention (0-10). For each scale, the higher the score the more prominent the negative symptoms were. The slopes were obtained by plotting the group SANS total score mean for treatment vs. placebo on Baseline, Week 4, and Week 8 and performing a random slopes model.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Diagnosis of Schizophrenia as per DSM IV criteria
- Have been treated for at least 6 months with any conventional neuroleptic
- Have prominent negative symptoms as defined by a total score of 40 or greater on the scale for the assessment of negative symptoms (SANS)
Exclusion Criteria:
- Active alcohol or drug abuse
- Unstable Medical Illness, seizure disorder, or other serious neurological disorder
- Pregnant or Nursing
- Unable to complete a cognitive battery

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000371
Principal Investigator: | Donald Goff, MD |
Responsible Party: | Donald C. Goff, MD, Director of the Schizophrenia Clinical and Research Program, Massachusetts General Hospital |
ClinicalTrials.gov Identifier: | NCT00000371 |
Other Study ID Numbers: |
R01MH054245-01A2 ( U.S. NIH Grant/Contract ) |
First Posted: | November 3, 1999 Key Record Dates |
Results First Posted: | September 10, 2014 |
Last Update Posted: | September 10, 2014 |
Last Verified: | September 2014 |
Adult Cognition Cycloserine Dopamine Female Glutamic Acid Human Male Receptors, N-Methyl-D-Aspartate Schizophrenia |
Serotonin Quality of Life Cycloserine -- *therapeutic use Dopamine -- blood Dopamine -- cerebrospinal fluid Glutamic Acid -- blood Glutamic Acid -- cerebrospinal fluid Serotonin -- blood Serotonin -- cerebrospinal fluid |
Schizophrenia Schizophrenia Spectrum and Other Psychotic Disorders Mental Disorders Cycloserine Anti-Infective Agents, Urinary Anti-Infective Agents |
Renal Agents Antibiotics, Antitubercular Antitubercular Agents Anti-Bacterial Agents Antimetabolites Molecular Mechanisms of Pharmacological Action |